SPIRIT-HF

Double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate efficacy and safety of spironolactone compared to placebo on composite endpoint of recurrent HF hospitalizations and CV death in patients with HF with mid- range or preserved ejection fraction